Studies imply that high tumor expression of activin A (a homodimer of inhibin beta A) is associated with poor prognosis in patients with CRC, and activin A receptor type 2A (ACVR2A) (a membrane receptor in the TGF-β signaling pathway) depletion plays an important role in CRC distant metastasis and may be recommended as a prognostic biomarker in CRC patients [172,173]. This evidence concerns the gene ACVR2A and colorectal carcinoma.